140 related articles for article (PubMed ID: 24879506)
1. Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors.
Kim N; Kwak SH; Lee SH; Juvekar V; Lee BI; Ahn HC; Kim SY; Gong YD
Org Biomol Chem; 2014 Jul; 12(27):4932-40. PubMed ID: 24879506
[TBL] [Abstract][Full Text] [Related]
2. A novel 3-arylethynyl-substituted pyrido[2,3,-b]pyrazine derivatives and pharmacophore model as Wnt2/β-catenin pathway inhibitors in non-small-cell lung cancer cell lines.
Gong YD; Dong MS; Lee SB; Kim N; Bae MS; Kang NS
Bioorg Med Chem; 2011 Sep; 19(18):5639-47. PubMed ID: 21855350
[TBL] [Abstract][Full Text] [Related]
3. Novel 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitriles, the promising protein kinase inhibitors with antiproliferative activity.
Dubinina GG; Platonov MO; Golovach SM; Borysko PO; Tolmachov AO; Volovenko YM
Eur J Med Chem; 2006 Jun; 41(6):727-37. PubMed ID: 16675067
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.
Lee SH; Kim N; Kim SJ; Song J; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1279-94. PubMed ID: 23604466
[TBL] [Abstract][Full Text] [Related]
5. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
Kim DS; Park KS; Jeong KC; Lee BI; Lee CH; Kim SY
Cancer Lett; 2009 Jan; 273(2):243-9. PubMed ID: 18804908
[TBL] [Abstract][Full Text] [Related]
6. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY
Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541
[TBL] [Abstract][Full Text] [Related]
7. Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines.
Myadaraboina S; Alla M; Saddanapu V; Bommena VR; Addlagatta A
Eur J Med Chem; 2010 Nov; 45(11):5208-16. PubMed ID: 20832916
[TBL] [Abstract][Full Text] [Related]
8. Cinnamoyl inhibitors of tissue transglutaminase.
Pardin C; Pelletier JN; Lubell WD; Keillor JW
J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
[TBL] [Abstract][Full Text] [Related]
9. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.
Pardin C; Roy I; Lubell WD; Keillor JW
Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232
[TBL] [Abstract][Full Text] [Related]
10. GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3).
Hitomi K; Ikura K; Maki M
Biosci Biotechnol Biochem; 2000 Mar; 64(3):657-9. PubMed ID: 10803976
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel target for renal cell carcinoma: transglutaminase 2.
Kang JH; Lee SH; Kim SY
Cell Death Dis; 2016 Apr; 7(4):e2200. PubMed ID: 27100894
[No Abstract] [Full Text] [Related]
12. Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
Zhang YB; Wang XL; Liu W; Yang YS; Tang JF; Zhu HL
Bioorg Med Chem; 2012 Nov; 20(21):6356-65. PubMed ID: 23018096
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.
Mukaiyama H; Nishimura T; Kobayashi S; Ozawa T; Kamada N; Komatsu Y; Kikuchi S; Oonota H; Kusama H
Bioorg Med Chem; 2007 Jan; 15(2):868-85. PubMed ID: 17095233
[TBL] [Abstract][Full Text] [Related]
14. Novel imidazo[1,2-a]pyrazine derivatives as potent reversible inhibitors of the gastric H+/K+-ATPase.
Zimmermann PJ; Brehm C; Buhr W; Palmer AM; Volz J; Simon WA
Bioorg Med Chem; 2008 Jan; 16(1):536-41. PubMed ID: 17964794
[TBL] [Abstract][Full Text] [Related]
15. New target against inflammatory diseases: transglutaminase 2.
Kim SY
Arch Immunol Ther Exp (Warsz); 2004; 52(5):332-7. PubMed ID: 15507874
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of Novel Methyl 7-[(Hetero)arylamino]thieno[2,3-
Rodrigues JM; Calhelha RC; Nogueira A; Ferreira ICFR; Barros L; Queiroz MRP
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443411
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship study of novel tissue transglutaminase inhibitors.
Duval E; Case A; Stein RL; Cuny GD
Bioorg Med Chem Lett; 2005 Apr; 15(7):1885-9. PubMed ID: 15780627
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of pyrazine-based CK2 inhibitors: synthesis and evaluation of 2,6-disubstituted pyrazines and 4,6-disubstituted pyrimidines.
Suzuki Y; Cluzeau J; Hara T; Hirasawa A; Tsujimoto G; Oishi S; Ohno H; Fujii N
Arch Pharm (Weinheim); 2008 Sep; 341(9):554-61. PubMed ID: 18763715
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiproliferative evaluation of some new amidino-substituted bis-benzothiazolyl-pyridines and pyrazine.
Racané L; Kraljević Pavelić S; Ratkaj I; Stepanić V; Pavelić K; Tralić-Kulenović V; Karminski-Zamola G
Eur J Med Chem; 2012 Sep; 55():108-16. PubMed ID: 22841279
[TBL] [Abstract][Full Text] [Related]
20. Solid-Phase Parallel Synthesis of N-Substituted-2-aminothiazolo[4,5-b]pyrazine Derivatives via Tandem Reaction of Isothiocyanate Terminated Resin with o-Bromo-2-Aminopyrazines.
Abdildinova A; Yang SJ; Gong YD
ACS Comb Sci; 2016 Dec; 18(12):702-709. PubMed ID: 27783481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
